Fungal Infections, also called mycoses, are infections caused by fungi, organisms that belong to a distinct biological kingdom separate from animals, plants, bacteria, and viruses. Fungi include yeasts, moulds, and other forms, and some species can switch between morphological states depending on environmental conditions. Human fungal disease ranges from superficial infections affecting skin, hair, or nails to invasive infections involving internal organs and the bloodstream.
Common examples include dermatophyte infections such as athlete's foot, candidiasis caused by Candida species, and invasive aspergillosis caused by Aspergillus species. The clinical significance of a fungal infection depends heavily on the site of infection and the host's immune status. Some fungi normally inhabit the human body without causing disease but can become pathogenic when local barriers, microbial communities, or immune defences are disrupted.
Fungi have eukaryotic cells containing nuclei and other membrane-bound organelles, making them biologically more similar to humans than bacteria are in several respects. Their cell walls commonly contain chitin and glucans, while their cell membranes contain ergosterol, an important target for several antifungal drugs. Yeasts are generally unicellular, whereas moulds form filamentous structures called hyphae that can collectively form a mycelium. Dermatophytes specialise in keratinised tissues and therefore commonly infect skin, hair, and nails. Dimorphic fungi can exist in different forms under different environmental conditions, a property that can be important for pathogenicity and diagnosis. These biological characteristics distinguish fungi from bacteria and explain why antifungal treatment requires different drug classes and mechanisms.
Fungal Infections can be classified by the depth and anatomical site of infection. Superficial and cutaneous mycoses mainly affect keratinised tissues and often produce scaling, itching, discolouration, or changes to nails and hair. Mucosal infections can affect sites such as the mouth or genital tract, while subcutaneous infections can follow traumatic implantation of environmental fungi into tissue. Systemic or invasive mycoses can disseminate through the bloodstream or affect organs such as the lungs and central nervous system.
Opportunistic fungal infections are particularly important in people with impaired immunity, including some individuals receiving chemotherapy, transplantation medicines, corticosteroids, or other immunosuppressive treatments. The same fungal genus can therefore be associated with very different clinical presentations depending on species, exposure, anatomical site, and host susceptibility.
Transmission differs according to the fungal organism and infection type. Dermatophytes can spread through direct contact with infected skin, contaminated surfaces, clothing, towels, or shared equipment, while some fungi are acquired by inhaling spores from environmental sources such as soil or decaying vegetation. Certain Candida infections arise from organisms already present on or within the body rather than from transmission between people. Fungi can also enter tissue through traumatic injury, particularly when contaminated soil or plant material is involved.
Environmental conditions such as warmth, moisture, poor ventilation, and occlusion can promote certain superficial infections. Prevention therefore depends on the route of acquisition and may involve keeping vulnerable skin dry, avoiding sharing personal items, using appropriate protective equipment during high-risk environmental exposure, and controlling underlying factors that predispose to opportunistic disease.
Diagnosis of Fungal Infections requires distinguishing fungi from bacterial, viral, inflammatory, and other causes of similar symptoms. Depending on the infection, clinicians may examine skin scrapings, nail clippings, hair, respiratory specimens, blood, cerebrospinal fluid, or tissue. Microscopy can reveal fungal structures, while culture allows growth and identification of the organism. Histopathology can demonstrate fungi within tissue, and molecular or antigen-based methods can assist with diagnosis of particular invasive infections. Because fungal cultures can take time and colonisation does not always indicate invasive disease, interpretation requires clinical context. In some serious infections, clinicians may begin treatment before definitive identification if the probability and consequences of invasive fungal disease justify empiric therapy.
Antifungal drugs target fungal-specific or relatively fungal-selective structures and processes. Azoles interfere with ergosterol synthesis, polyenes bind ergosterol and disrupt fungal membranes, echinocandins inhibit synthesis of important cell-wall glucans, and other agents act through different mechanisms. Treatment choice depends on the organism, infection site, disease severity, immune status, drug interactions, resistance patterns, and ability of the medicine to penetrate affected tissues. Some superficial infections can be treated with topical preparations, while invasive disease often requires systemic therapy and prolonged treatment. Antifungal resistance is an increasing concern because mutations, selection pressure, biofilm formation, and other mechanisms can reduce susceptibility. Treatment can also be complicated by toxicity and interactions because fungal cells share many biochemical pathways with human cells.
Risk factors for serious Fungal Infections include immune suppression, disruption of anatomical barriers, prolonged hospitalisation, invasive medical devices, certain chronic illnesses, broad-spectrum antibiotic exposure, and particular environmental exposures. Antibiotics can indirectly predispose to some fungal overgrowth by altering bacterial communities that normally compete with fungi. Invasive candidiasis can occur in severely ill hospitalised patients, while invasive mould infections can be particularly dangerous in people with profound immune impairment.
Severe fungal disease is not limited to people who have obvious immune deficiency, however, and risk varies according to the organism and clinical setting. Public-health and infection-control measures can include environmental controls, appropriate device care, antimicrobial stewardship, surveillance, and early recognition of high-risk clinical presentations.
Fungal Infections are often misunderstood because many common fungal diseases are mild and superficial, whereas others can be life-threatening. The term "fungus" does not imply that an infection is necessarily contagious, and many clinically important infections arise from environmental exposure or organisms already present in the body. Fungal infections also differ from bacterial infections in their cellular biology, which is why antibiotics are ineffective against fungi and why antifungal medicines have distinct targets.
Historically, fungal diseases were often difficult to diagnose and treat, but microscopy, culture, molecular identification, improved imaging, and newer antifungal drugs have substantially expanded diagnostic and therapeutic capabilities. Understanding Fungal Infections therefore requires attention to fungal biology, morphology, anatomical site, route of acquisition, host immunity, diagnostic method, and drug susceptibility rather than treating all fungal disease as one uniform category.
